Trials / Completed
CompletedNCT00153790
LEAN Project: Weight Loss and Appetite Suppression
The Effect of Soy Lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and Green Tea-derived Epigallocatechin Gallate (EGCG) on Indices of Weight Loss and Appetite Suppression
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- The Cooper Institute · Academic / Other
- Sex
- Female
- Age
- 30 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary aim is to examine whether the intake of PhosphoLEAN is effective in aiding a cohort of women in losing weight. Participants taking the supplement will have significantly greater improvement in study outcomes than those taking the placebo.
Detailed description
Participants will be randomized to either a control or treatment group taking the dietary supplement containing a soy lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and caffeine free Green Tea-derived epigallocathchin gallate (EGCG) whose trade name is PhosphoLean. The outcome is to determine the effects on indices of weight loss and appetite suppression. Participants will return at 6, 12, and 16 weeks for clinical measures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PhosphoLean |
Timeline
- Start date
- 2005-04-01
- Completion
- 2006-05-01
- First posted
- 2005-09-12
- Last updated
- 2014-03-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00153790. Inclusion in this directory is not an endorsement.